[복지4.0] Trump vs. Bill Gates vs. Si Jinping … Which vaccine will come first?

The development of the vaccine generally takes 10-12 years. In the case of the corona vaccine, not so long ago, “even the most optimistic prospects” This year and next year, was the “hope advisor” environment. But these days it has changed. It is predicted that the time to develop vaccines could be longer than expected due to the full financial and procedural support of governments like the United States, the fight for power of the main pharmaceutical companies around the world and the rapid development of technology. of life sciences.

Currently, the most optimistic prospect is President Donald Trump. “I think I will have a vaccine by the end of this year,” Trump said on the 14th (local time), answering questions with reporters at the Southron White House.

President Trump also said: “Almost at the same time the distribution (vaccination) will take place.” The White House is operating “Operation Warp Speed,” which distributes the vaccines by the end of the year.

Next up is the director of the National Institute of Allergy Infectious Diseases (NIAID), a member of the White House Corona Response Task Force (TF) and founder of Bill Gates, Microsoft (MS), in January of next year.

At the press conference on 30 (local time) last month, the exchange’s manager answered “yes” to the question: “Can it produce hundreds of millions of vaccines by January?” However, the director of the exchange declined the video hearing of the United States Senate on 12, saying: “At least eight candidates for the corona vaccine are in the clinical trial stage, but it takes time to determine if they really are effective. “

He said the National Institutes of Health said: “We are eager to know if we will be successful in late fall or early winter” about candidates for developing vaccines with Modena. Candidates in development for Modena vaccines are preparing for Phase 2 clinical trials by the US FDA. USA For the designation of fast track.

Bill Gates also posted on the website of his charitable foundation ‘Bill and Merlin Gates’ earlier this month that “a corona vaccine will be launched in the next nine months.” The next nine months will be around January of next year. It recently announced that it would sponsor some of the more than $ 40 billion (about 49 billion won) to develop corona vaccines.

“If everything goes as planned, some vaccines are likely to be ready for approval in early 2021, within a year,” said Marco Cavaleri, director of vaccines for the European Medicines Agency (EMA). .
“It is just a prediction based on what we are seeing,” he said. This is the case of the “best scenario”.

China is betting that corona vaccines could be developed at roughly the same time as the United States.
Gao Fu, China’s Center for Disease Control and Prevention (CDC), said last month 24: “In September, we will have a corona vaccine that can be used in an emergency.” Vaccines in Phase II or Phase III can be used for medical personnel and others. ” However, Gao also predicted that a publicly targeted corona vaccine will be available early next year.

In the case of Korea, three candidate substances, such as SK Bioscience and Genexin, will start clinical trials in the field of vaccines this year, officials from the Panggovernment Support Group for the development of therapies and vaccines said. It was suggested that the vaccine could be produced in the second half of 2021.

“It is difficult to judge whether it is possible because the government has not provided the basis for starting the clinical trial of the vaccines later this year,” said Kim Woo-joo, professor of infectious medicine at Daegu Guro Hospital. Said.

SK Bioscience is in the process of finding candidate substances and seeing if they are effective for animals. Clinical trials were expected to start in September. Seong Yeong-cheol, president of Genexine, said in an interview to the media: “We confirm that the vaccine candidate produced a neutralizing antibody capable of neutralizing the virus in monkeys. I expected. / Kim Min-cheol, senior reporter